肺p38シグナル遺伝子改変マウスのブレオマイシン誘導肺線維症に関するトランスクリプトーム解析：特発性肺線維症の新規治療標的の探索

• Published in: 日本薬理学会年会要旨集 p. 2-O-C1-1
• Main Authors: 松田, 周一, 金, 俊達, 杉山, 文博, 松尾, 祐志, 石田, 純治, 村田, 知弥, 中村, 夏奈子, 並木, 香奈, 須藤, 龍彦, 桑木, 共之, 幡野, 雅彦, 巽, 浩一郎, 深水, 昭吉, 粕谷, 善俊
• Format: Journal Article
• Language: Japanese
• Published: 公益社団法人 日本薬理学会 2021
• Subjects: lung; transgenic animal
• ISSN: 2435-4953
• DOI: 10.1254/jpssuppl.94.0_2-O-C1-1

p38 mitogen-activated protein kinase (MAPK) may contribute to the development of idiopathic pulmonary fibrosis (IPF) through its activation in alveolar epithelial type II cells (AEC II) in response to environmental stresses. We examined whether AEC II-specific　genetically modified p38 activity causes worsening of bleomycin (BLM)-induced pulmonary fibrosis and investigated the potential therapeutic targets for IPF progression by assessing its transcriptome. The three mouse genotypes having different p38 activity in AEC II, MKK6-constitutive active, wild type, and p38-dominant negative, received intratracheal administration of BLM and the lungs were analyzed at 8 days post-instillation, known as an active fibrosis phase. Increased histopathological severity, reduced compliance, and higher collagen content of the lungs correlated with increased p38 activity in AEC II. Transcriptome analysis of them revealed that the differentially expressed genes, upregulated by BLM and associated with upregulation of p38 MAPK pathway, were enriched for functions related to endoplasmic reticulum, extracellular matrix, and immune system. Comparison of our data with a publicly available IPF data determined the target genes involved in IPF progression. These findings indicate that p38 MAPK in AEC II plays an important role in IPF progression.